Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew

IMPACT FACTOR 2018: 1.221

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.329
Source Normalized Impact per Paper (SNIP) 2018: 0.479

ICV 2017: 152.94

Open Access
See all formats and pricing
More options …
Volume 9, Issue 2


Volume 10 (2015)

Intravascular large B-cell lymphoma with prominent cutaneous manifestation — case report

Ewa Stefanko
  • Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, 50-367, Wroclaw, Poland
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Tomasz Wróbel
  • Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, 50-367, Wroclaw, Poland
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-02-13 | DOI: https://doi.org/10.2478/s11536-013-0160-y


Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of extranodal diffuse large B-cell lymphoma (DLBCL) characterized by selective growth of neoplastic cells within the vascular lumen. IVLBCL involves all types of organs and mostly is associated with poor prognosis, but patients with cutaneous variant have significantly better survival. In this article we report a case of 80-year-old woman with prominent cutaneous manifestation of intravascular large B-cell lymphoma.

Keywords: Intravascular large B-cell lymphoma; Cutaneous variant

  • [1] Pfleger L, Tappeiner J. On the recognition of systematized endotheliomatosis of the cutaneous blood vessels (reticuloendotheliosis?) Hautarzt 1959; 10: 359–363 Google Scholar

  • [2] Pekic S, Milicevic S, Colovic N, Colovic M and Popovic V. Intravascular large B-cell lymphoma as a cause of hypopituitarism: gradual and late reversal of hypopituitarism after long-term remission of lymphoma with immunochemotherapy. Endocrine 2008; 34: 11–16 http://dx.doi.org/10.1007/s12020-008-9109-3CrossrefWeb of ScienceGoogle Scholar

  • [3] Narimatsu H, Morishita Y and Saito S, Shimada K, Ozeki K, Kohno A, Kato Y, Nagasaka T. Usefulness of bone marrow aspiration for definite diagnosis of Asian variant of intravascular lymphoma: four autopsied cases. Leuk Lymphoma 2004; 45: 1611–1616 http://dx.doi.org/10.1080/10428190410001683769CrossrefGoogle Scholar

  • [4] Ferreri AJ, Dognini GP and Campo E, Willemze R, Seymour JF, Bairey O, Martelli M, De Renz AO, Doglioni C, Montalban C, Tedeschi A, Pavlovsky A, Morgan S, Uziel L, Ferracci M, Ascani S, Gianelli U, Patriarca C, Facchetti F, Dalla Libera A Pertoldi B, Horvath B, szamor A, Zucca E, Cavalli F. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica 2007; 92: 486–492 http://dx.doi.org/10.3324/haematol.10829Web of ScienceCrossrefGoogle Scholar

  • [5] Roglin J, Boer A. Skin manifestations of intravascular lymphoma mimic inflammatory diseases of the skin. Br J Dermatol 2007; 157: 16–25 http://dx.doi.org/10.1111/j.1365-2133.2007.07954.xCrossrefWeb of ScienceGoogle Scholar

  • [6] Martusewicz-Boros M, Wiatr E, Radzikowska E, Roszkowski-Sliz K and Langfort R. Pulmonary intravascular large B-cell lymphoma as a cause of severe hypoxemia. J Clin Oncol 2007; 25: 2137–2139 http://dx.doi.org/10.1200/JCO.2007.10.7201CrossrefWeb of ScienceGoogle Scholar

  • [7] Fukushima A, Okada Y, Tanikawa T, Onaka T, Tanaka A, Higashi T, Tsukada J, Tanaka Y. Primary bilateral adrenal intravascular large B-cell lymphoma associated with adrenal failure. Intern Med 2003; 42: 609–614 http://dx.doi.org/10.2169/internalmedicine.42.609CrossrefWeb of ScienceGoogle Scholar

  • [8] Katalinic D, Valkovic T, Lucin K, Rudez J. Intravascular lymphoma and thyroid gland Coll Antropol 2006; 30: 239–241 Google Scholar

  • [9] Saleh Z, Kurban M, Ghosn S, Awar G, Kibbi AG. Generalized teleangiectasia: a manifestation of intravascular B-cell lymphoma. Dermatology 2008; 217: 318–320 http://dx.doi.org/10.1159/000151443Web of ScienceCrossrefGoogle Scholar

  • [10] Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, Zucca E, Rossi G, Lopez-Guillermo A, Pavlovsky MA, Geerts ML, Candoni A, Lestani M, Asioli S, Milani M, Piris MA, Pileri S, Facchetti F, Cavalli F, Ponzoni M. Intravascula lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the “cutaneous variant”. Br J Haematol. 2004; 127: 173–183 http://dx.doi.org/10.1111/j.1365-2141.2004.05177.xCrossrefGoogle Scholar

  • [11] Ponzoni M, Ferreri AJ, Campo E, Facchetti F, Mazzucchelli L, Yoshino T, Murase T, Pileri SA, Doglioni C, Zucca E, Cavalli F, Nakamura S. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol 2007; 25: 3168–3173 http://dx.doi.org/10.1200/JCO.2006.08.2313Web of ScienceCrossrefGoogle Scholar

  • [12] Colovic N, Jurisic V, Terzic T, Atkinson HD, Colovic M. Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin’s lymphoma. Arch Dermatol Res. 2009; 301:689–92 http://dx.doi.org/10.1007/s00403-009-0967-1CrossrefWeb of ScienceGoogle Scholar

  • [13] Shimada K, Matsue K, Yamamoto K, Murase T, Ichikawa N, Okamoto M, Niitsu N, Kosugi H, Tsukamoto N, Miwa H, Asaoku H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Ymaguchi M, Nakamura S, Naoe T, Kinoshita T. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 2008; 26: 3189–3195 http://dx.doi.org/10.1200/JCO.2007.15.4278CrossrefGoogle Scholar

  • [14] Ferreri AJ, Dognini GP, Bairey O, Szomor A, Montalban C, Horvath B, Demeter J, Uziel L, Soffietti R, Seymour JF, Ambrosetti A, Willemze R, Martelli M, Rossi G, Candoni A, De Renzo A, Doglioni C, Zucca E, Cavalli F, Ponzoni M. The addition of rituximab to anthracyclines-based chemotherapy significantly improves outcome in “Western” patients with intravascular large B-cell lymphoma. Br J Haematol 2008; 143: 253–257 http://dx.doi.org/10.1111/j.1365-2141.2008.07338.xWeb of ScienceCrossrefGoogle Scholar

  • [15] Masaki Y, Dong L, Nakajima A, Iwao H, Miki M, Kurose N, Kinoshita E, Nojima T, Sawaki T, Kawanami T, Tanaka M, Shimoyama K, Kim C, Fukutoku M, Kawabata H, Fukushima T, Hirose Y, Takiguchi T, Konda S, Sugai S, Sugai S, Umehara H. Intravascular large B-cell lymphoma proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition. Int J Hematol 2009; 89: 600–610 http://dx.doi.org/10.1007/s12185-009-0304-7CrossrefGoogle Scholar

About the article

Published Online: 2014-02-13

Published in Print: 2014-04-01

Citation Information: Open Medicine, Volume 9, Issue 2, Pages 200–203, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-013-0160-y.

Export Citation

© 2014 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in